Jean-Charles Grivel, PhD

Principal Investigator – Associate Level | Director
Director - Deep Phenotyping Core
Deep Phenotyping Core

Email: jgrivel (@) sidra.org
Phone: +974 40037407

  • Biography

    Dr Jean-Charles Grivel obtained a Ph.D. in immunology from the University of Aix Marseille II in 1993. He was a postdoctoral fellow at the National Cancer Institute (NIH, USA) and became a Staff Scientist in 2000 at the National Institute of Child Health and Human Development. He pioneered the development of human organ culture for studying the pathogenesis of HIV, Human Herpes Viruses and Measles virus as well as their interactions, which led to the granting of two patents. Dr Grivel has developed several high dimension immunoassays for the quantification of viral antigens and other immune system related proteins. He has also developed several flow cytometric methods for characterizing antigen-specific cellular responses as well as submicron particles. These methods are used for studying the role of microvesicles in heath and disease, especially in cardiovascular disease and cancer as well as to characterize the antigenic composition and maturation of viral particles. Dr Grivel has received the NIH Award of Merit in 2006. Dr Grivel has authored 94 peer reviewed publications, mentored several PhD students and postdoctoral fellows. He currently directs the Deep Phenotyping of Sidra Medicine holds an Adjunct Associate Professor position at Hama Bin Khakifa University in Doha.
  • Our Research and Approach

    The Deep Phenotyping Core (DPC), comprises a Flow Cytometry core, an Analytical Chemistry Laboratory (ACL), a proteomic core and an Advanced Imaging Core (AIC). The Flow Cytometry Core develops complex immuno-phenotyping panels on a 60+ channel color cell analyzer and a 31-parameter cell sorter. The ACL is specialized in metabolomics and Lipidomics, the AIC performs super-resolution and dual-photons excitation for intra-vital imaging. Finally, the DPC is a certified SomaScan site and performs high dimension bead arrays protein profiling for biomarker discovery. The research activities of the DPC focus on delivering a precise cellular or molecular phenotyping of patients by performing services analyses that extend and complement those routinely provided by Sidra’s pathology department as it is the case for Sperm DNA fragmentation, and a COVID19 seroconversion assay. The expertise of the group members together with the unique technical platform of the DPC allow for research activities focused on the understanding of the role of microvesicles in pathophysiological processes by characterizing their content, their surface markers and their lipid composition.
  • Lab Members

    Shana Jacob 
    Manager Analytical Chemistry Laboratory  
    Email: sjacob (@) sidra.org  

    Saroja Kotegar Balayya  
    Research Specialist IV Analytical Chemistry Laboratory  
    Email: skotegarbalayya (@) sidra.org  

    Abbirami Sathappan  
    Research Specialist II, Advanced Imaging Core  
    Email: asthappan (@) sidra.org  

    Igor Pavlovski  
    Research Specialist III, Proteomic and Flow Cytometry Core  
    Email: ipavlovski (@) sidra.org  

    Selma Maacha  
    Post-Doctoral Fellow, Proteomic and Flow Cytometry Core  
    Email: smaacha (@) sidra.org

Selected publications (co-first, *corresponding):

  • Maacha S, Bhat AA, Jimenez L, Raza A, Haris M, Uddin S, and Grivel JC*. Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Molecular cancer. 2019;18(1):55.
  • Zicari S, Arakelyan A, Fitzgerald W, Zaitseva E, Chernomordik LV, Margolis L, and Grivel JC*. Evaluation of the maturation of individual Dengue virions with flow virometry. Virology. 2016;488:20-7.
  • Fitzgerald W, and Grivel JC*. A universal nanoparticle cell secretion capture assay. Cytometry A. 2013;83(2):205-11.
  • Arakelyan A, Fitzgerald W, Margolis L, and Grivel JC*. Nanoparticle-based flow virometry for the analysis of individual virions. The Journal of clinical investigation. 2013;123(9):3716-27.
  • Grivel JC, and Margolis L. Use of human tissue explants to study human infectious agents. Nature protocols. 2009;4(2):256-69.
  • Biancotto A, Iglehart SJ, Vanpouille C, Condack CE, Lisco A, Ruecker E, Hirsch I, Margolis L, and Grivel JC. HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood. 2008;111(2):699-704.
  • Münch J, Rücker E, Ständker L, Adermann K, Goffinet C, Schindler M, WildumS, Chinnadurai R, Rajan D, Specht A, Giménez-Gallego G, Sánchez PC, Fowler DM,Koulov A, Kelly JW, Mothes W, Grivel JC, Margolis L, Keppler OT, Forssmann WG,Kirchhoff F. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell. 2007;131(6):1059-71.
  • Grivel JC, Ito Y, Faga G, Santoro F, Shaheen F, Malnati MS, et al. Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat Med. 2001;7(11):1232-5.
  • Penn ML, Grivel JC, Schramm B, Goldsmith MA, and Margolis L. CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proc Natl Acad Sci U S A. 1999;96(2):663-8.
  • Grivel JC, and Margolis LB. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue. Nat Med. 1999;5(3):344-6.